Semaglutide vs. tirzepatide at Join Luma

Begin with your current situation: are you new to GLP-1 treatment, continuing medication, or considering a change because of tolerability or practical concerns? Bring the exact medication, dose, last dose date, and recent side effects to intake. A photograph of your current prescription label can help prevent confusion between milligrams and syringe units.

Join Luma’s clinician reviews the intake before anything is prescribed, and patients are charged only if treatment is approved. The decision is not a shopping-cart selection that bypasses medical review. Your clinician can discuss whether a compounded formulation is appropriate and how the options fit your health history.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts at both GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptors. These incretin pathways help regulate appetite and glucose-related physiology. A dual mechanism does not mean the appropriate starting amount is higher or that one medication is automatically the right fit for everyone.

FDA-approved branded products containing these ingredients have their own approved indications, formulations, and instructions. Join Luma’s compounded preparations are not FDA-approved Wegovy, Ozempic, Zepbound, or Mounjaro, and they are not FDA-approved generics of those brands. See the FDA explanation of compounded drugs for that distinction.

For a broad scientific comparison, read semaglutide versus tirzepatide. This guide instead focuses on the program decisions you can discuss at Join Luma: the prescription, plan, preparation, pharmacy, and routine you would actually use.

The 2025 NEJM SURMOUNT-5 report compared branded tirzepatide and semaglutide obesity treatment in adults with obesity without diabetes. At 72 weeks, the reported mean percentage weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide. These are group averages from a controlled study, not a forecast for an individual.

The study used the branded injectable treatment programs associated with Zepbound and Wegovy at maximum tolerated study doses. It did not study Join Luma patients, compounded injections, or compounded oral dissolving tablets. Its result therefore supports a discussion of the branded evidence without establishing equivalent outcomes for a compounded formulation.

Participants’ tolerability and clinical characteristics also matter when interpreting an average. The practical question is not simply which trial number is larger, but which treatment your clinician considers appropriate and sustainable for you. No Join Luma outcome or review data are claimed here.

Both ingredients can cause gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort. In SURMOUNT-5, gastrointestinal events were common in both branded-treatment groups and occurred especially during dose escalation. Individual experience varies; prior tolerance of one drug does not guarantee the same experience with another.

Discuss a personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, gallbladder problems, significant digestive symptoms, pregnancy plans, and other medicines. The Wegovy label provides branded semaglutide safety information; your clinician should review the complete relevant safety considerations for your actual prescription.

Seek urgent care for severe abdominal pain or signs of dehydration, and call 911 for a severe allergic reaction. Do not wait for a routine portal reply for severe symptoms. For nonurgent tolerability questions, contact the clinician rather than changing the dose yourself.

For patients new to GLP-1 medication, the three-month plan is $99/month for compounded semaglutide and $149/month for compounded tirzepatide. The upfront amounts are $297 and $447, respectively; Affirm, Klarna, or Afterpay can split the payment, subject to approval.

The new-patient price is designed to help patients get started and applies to the first plan period. Plans then renew at affordable Current GLP User pricing for the same commitment length: the three-month rates are $119/month for semaglutide and $179/month for tirzepatide. Current-user monthly options are $149 and $219, respectively.

Current GLP-1 users can choose six-month prepaid injection plans at $99/month for semaglutide, $594 total, or $149/month for tirzepatide, $894 total. Affirm, Klarna, or Afterpay can split the payment, subject to approval. Plans include clinician oversight, medication if prescribed, necessary supplies, and shipping, with no membership fees and the same price every dose.

Check current pricing for the available commitment lengths and oral ODT plans. Compare a manageable ongoing plan, not just the first monthly figure. Contact support before the next billing date if you want to change commitment length.

For compounded injections, Hallandale prepares the additive-free option and VialsRx prepares formulations with glycine or vitamin B12. Patients choose a formulation and the clinician confirms it. Hallandale does not serve Alabama, Arkansas, California, Hawaii, Kansas, Massachusetts, Michigan, Minnesota, or Mississippi; VialsRx is the listed Join Luma pharmacy in those states.

Both partners are described as licensed 503A pharmacies supplying patient-specific prescriptions. The FDA GLP-1 compounding policy explains why the end of shortage-related discretion and essentially-copy conditions still matter. An additive does not automatically establish a patient-specific significant difference or promise better tolerability.

Read the pharmacy partner overview. Hallandale lists several concentrations, while VialsRx concentrations are on the prescription label. If medication or concentration changes, the old syringe units may no longer apply. Follow the new label rather than carrying a previous number forward.

Join Luma’s compounded semaglutide ODT and tirzepatide ODT are once-daily dissolving tablets built in with ondansetron for anti-nausea support. Weekly injections and daily ODTs are different routines and formulations. Discuss whether the oral preparation is appropriate; do not apply injectable trial results or milligram conversions to the tablet.

The oral option page explains the program’s format. Compounded ODTs are not the same product as an FDA-approved oral semaglutide tablet, and ondansetron does not guarantee absence of nausea. Tell the clinician about other medications so ingredient-specific precautions can be considered.

You can ask the clinician about switching later, but do not overlap medications or convert doses yourself. There is no universal milligram-for-milligram switch. Share your current dose, last administration date, and symptoms so the clinician can provide individualized directions. The FDA dosing-error alert is a useful reminder that concentration and measurement deserve a fresh check whenever treatment changes.